Status:
RECRUITING
Glioblastoma Targeted Treatment Option Maximization by WGS
Lead Sponsor:
UMC Utrecht
Collaborating Sponsors:
Amsterdam University Medical Center
The Netherlands Cancer Institute
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
In Dutch centers performing neurosurgery on and/or treating GBM, all recurrent GBM patients are discussed in local tumor boards and this setup will be used to effectively identify possible GLOW study ...
Detailed Description
Rationale: Glioblastoma (GBM), the most common primary brain tumor, is without exception lethal. Every year 1000 patients are diagnosed with this disease in the Netherlands. Despite neurosurgery, chem...
Eligibility Criteria
Inclusion
- Histopathologically confirmed IDH wild type glioblastoma, first recurrence after standard chemoradiation; suitable for standard-of-care re-resection;
- Age ≥ 18 years;
- Able and willing to give written informed consent;
- Life expectancy \>3 months, allowing adequate follow-up of toxicity evaluation and antitumor activity;
- KPS performance status ≥70.
Exclusion
- Currently actively treated in another antitumor clinical trial (excluding DRUP and STELLAR studies);
- Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in medication studies or which could jeopardize compliance with study requirements including, but not limited to ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness/social situations.
Key Trial Info
Start Date :
July 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05186064
Start Date
July 25 2022
End Date
July 1 2025
Last Update
May 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Haaglanden Medisch Centrum
The Hague, Netherlands